BACKGROUND: Risk of invasive cancer following treatment for ductal carcinoma in situ (DCIS) is associated with both treatment- and tumor-related factors. However, it is unknown whether stromal factors such as breast density may also influence subsequent invasive breast events. We investigated whether breast density is an independent predictor of subsequent breast events among women treated for DCIS. POPULATION: A prospective cohort study of 3,274 women ages 30 to 93 in the Breast Cancer Surveillance Consortium treated with lumpectomy for DCIS between 1993 and 2005. All subjects had an American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) breast density measure recorded prior to diagnosis. METHODS: Ipsilateral and contralateral breast cancer following lumpectomy for DCIS were ascertained through state tumor registries, regional Surveillance Epidemiology and End Results program or pathology databases. A Cox proportional hazard model was used to compare adjusted risk of breast cancer among women with high (BI-RADS 3 or 4) versus low (BI-RADS 1 or 2) breast density. RESULTS: During a median follow-up period of 39 months (0-132 months), 133 women developed invasive breast cancer. After adjusting for age and radiation treatment, high breast density was associated with increased hazard for contralateral (hazard ratio, 3.1; 95% confidence interval, 1.6-6.1) but not ipsilateral (hazard ratio, 1.0; 95% confidence interval, 0.6-1.6) invasive breast events. CONCLUSION: High breast density is associated with contralateral, but not ipsilateral, invasive breast cancer following lumpectomy for DCIS. Thus, women with DCIS and high breast density may especially benefit from antiestrogenic therapy to reduce the risk of contralateral invasive disease.
BACKGROUND: Risk of invasive cancer following treatment for ductal carcinoma in situ (DCIS) is associated with both treatment- and tumor-related factors. However, it is unknown whether stromal factors such as breast density may also influence subsequent invasive breast events. We investigated whether breast density is an independent predictor of subsequent breast events among women treated for DCIS. POPULATION: A prospective cohort study of 3,274 women ages 30 to 93 in the Breast Cancer Surveillance Consortium treated with lumpectomy for DCIS between 1993 and 2005. All subjects had an American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) breast density measure recorded prior to diagnosis. METHODS: Ipsilateral and contralateral breast cancer following lumpectomy for DCIS were ascertained through state tumor registries, regional Surveillance Epidemiology and End Results program or pathology databases. A Cox proportional hazard model was used to compare adjusted risk of breast cancer among women with high (BI-RADS 3 or 4) versus low (BI-RADS 1 or 2) breast density. RESULTS: During a median follow-up period of 39 months (0-132 months), 133 women developed invasive breast cancer. After adjusting for age and radiation treatment, high breast density was associated with increased hazard for contralateral (hazard ratio, 3.1; 95% confidence interval, 1.6-6.1) but not ipsilateral (hazard ratio, 1.0; 95% confidence interval, 0.6-1.6) invasive breast events. CONCLUSION: High breast density is associated with contralateral, but not ipsilateral, invasive breast cancer following lumpectomy for DCIS. Thus, women with DCIS and high breast density may especially benefit from antiestrogenic therapy to reduce the risk of contralateral invasive disease.
Authors: Marzana Chowdhury; David Euhus; Maureen O'Donnell; Tracy Onega; Pankaj K Choudhary; Swati Biswas Journal: Breast Cancer Res Treat Date: 2018-03-06 Impact factor: 4.872
Authors: Siun M Walsh; Sandra B Brennan; Emily C Zabor; Laura H Rosenberger; Michelle Stempel; Lizza Lebron-Zapata; Mary L Gemignani Journal: Ann Surg Oncol Date: 2019-08-08 Impact factor: 5.344
Authors: Steven R Cummings; Jeffrey A Tice; Scott Bauer; Warren S Browner; Jack Cuzick; Elad Ziv; Victor Vogel; John Shepherd; Celine Vachon; Rebecca Smith-Bindman; Karla Kerlikowske Journal: J Natl Cancer Inst Date: 2009-03-10 Impact factor: 13.506
Authors: Laurel A Habel; James J Dignam; Stephanie R Land; Martine Salane; Angela M Capra; Thomas B Julian Journal: J Natl Cancer Inst Date: 2004-10-06 Impact factor: 13.506
Authors: Nehmat Houssami; Linn A Abraham; Karla Kerlikowske; Diana S M Buist; Les Irwig; Janie Lee; Diana L Miglioretti Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-19 Impact factor: 4.254
Authors: Tracy Onega; Elisabeth F Beaber; Brian L Sprague; William E Barlow; Jennifer S Haas; Anna N A Tosteson; Mitchell D Schnall; Katrina Armstrong; Marilyn M Schapira; Berta Geller; Donald L Weaver; Emily F Conant Journal: Cancer Date: 2014-05-15 Impact factor: 6.860